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ABSTRACT
Objectives: There has not previously been a systematic
comparison of awards for research funding in infectious
diseases by sex. We investigated funding awards to UK
institutions for all infectious disease research from 1997
to 2010, across disease categories and along the
research and development continuum.
Design: Systematic comparison.
Methods: Data were obtained from several sources for
awards from the period 1997 to 2010 and each study
assigned to—disease categories; type of science
(preclinical, phases I–III trials, product development,
implementation research); categories of funding
organisation. Fold differences and statistical analysis were
used to compare total investment, study numbers, mean
grant and median grant between men and women.
Results: 6052 studies were included in the final
analysis, comprising 4357 grants (72%) awarded to men
and 1695 grants (28%) awarded to women, totalling
£2.274 billion. Of this, men received £1.786 billion
(78.5%) and women £488 million (21.5%). The median
value of award was greater for men (£179 389; IQR
£59 146–£371 977) than women (£125 556; IQR
£30 982–£261 834). Awards were greater for male
principal investigators (PIs) across all infectious disease
systems, excepting neurological infections and sexually
transmitted infections. The proportion of total funding
awarded to women ranged from 14.3% in 1998 to 26.8%
in 2009 (mean 21.4%), and was lowest for preclinical
research at 18.2% (£285.5 million of £1.573 billion) and
highest for operational research at 30.9% (£151.4 million
of £489.7 million).
Conclusions: There are consistent differences in
funding received by men and women PIs: women have
fewer funded studies and receive less funding in absolute
and in relative terms; the median funding awarded to
women is lower across most infectious disease areas, by
funder, and type of science. These differences remain
broadly unchanged over the 14-year study period.
INTRODUCTION
Women are under-represented in biomedical
science, yet few studies have systematically
explored the extent and reasons for the
observed differences between men and
women scientists. Women comprise 50% of
the European Union (EU) student popula-
tion and 45% of doctoral students, but only
one-third of career researchers are women—
a ﬁgure that is lower for senior positions.1
In 2001, a Wellcome Trust survey concluded
that although women were as successful as
men in securing funding for biomedical
research, they were less likely to apply for grant
funds because of their status in scientiﬁc insti-
tutions and the level of support they received.2
An analysis of Wellcome Trust awards in 2000–
2008 revealed a signiﬁcant gender difference
in the amount of funding awarded, even after
adjusting for the seniority of the principal
investigator (PI), concluding “the most likely
explanation for the difference in amounts
awarded to women and men is that women are
Strengths and limitations of this study
▪ This is the first study to present detailed data
and rigorously quantify funding differences
between men and women researchers in infec-
tious disease research in the UK.
▪ Our results provides new and additional evidence
on differences on funding for men and women
researchers highlighted in earlier studies and
provides a case for new research to explain
the source of these differences, especially given
the government commitments to increase the
number of women in science.
▪ We were unable to assess the success and
failure rates by gender and thus cannot
comment on the extent of inequalities or bias.
As we could not feasibly access data on the aca-
demic ranking of principal investigators, we were
hence unable to adjust for levels of seniority
across both genders. A follow-up study incorpor-
ating these data would allow for more meaning-
ful conclusions to be drawn about the nature of
any possible disparities.
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systematically less ambitious in the amounts of funding
requested in their grant applications.”3 In 2011, around
44% of academics in UK universities were women, yet only
39% of senior lecturers and 19% of professors were
women.4 Furthermore, a number of studies from the USA
have shown that women in science are disadvantaged com-
pared to men.5–7
The low numbers of women in science and the
reasons for this anomaly are a matter of concern for
scientists and policy-makers. Although the UK Medical
Research Council (MRC) has a gender equality scheme,
which brieﬂy states that gender equality is reﬂected
in agreements with research organisations receiving
MRC funding, it is not clear how the scheme is
implemented.8
While several initiatives have aimed to increase the
numbers of women involved in science, there are no
afﬁrmative actions or binding policies in the UK or
Europe to deﬁnitively ensure that women are better
represented in science. Indeed, some initiatives aimed at
increasing women in science have been criticised. For
example, in 2012, the European Commission campaign
targeting 13-year-old to 18-year-old secondary school stu-
dents9 was rebuked and described as an insult to women
in science,10 11 with the offending video clip removed
from the EU campaign website. The effects of cam-
paigns aimed at raising the proﬁle of women in
science12 13 have not been assessed.
We have previously undertaken a systematic analysis of
research funding awarded to UK institutions for all infec-
tious disease research for the 14-year period from 1997 to
2010.14 Here, we use the dataset gathered for this earlier
study to examine trends over time, the distribution of
funding awarded to men and women PIs across speciﬁc
infections, funder categories and along the research and
development (R&D) continuum, extending from preclin-
ical to clinical and operational research.
METHODS
We obtained data from several sources for infectious
disease research studies where funding was awarded
between 1997 and 2010. The methods for the original
study are elaborated in detail elsewhere14 and sum-
marised here. We identiﬁed 325 922 studies for screen-
ing that covered all areas of disease from several
funders, and ﬁltered these to identify funding for infec-
tious diseases where the lead institution was in the UK
in the period and the year of award 1997–2010. We
obtained data from publicly available sources and dir-
ectly from the funders. We did not include private sector
funding in the analysis, as pharmaceutical sector data
were not publicly available. Figure 1 shows the sources of
data and the numbers of studies included and excluded
at each stage of screening to reach the ﬁnal set of
studies for detailed analysis.
Data collection and cleaning took place alongside
routine duties between 2006 and 2011, primarily by
MGH and assisted by JRF, MKC and FBW. Funding
records could feasibly be obtained going back to 1997,
hence the decision to cover awards during 1997–2010.
We assigned each study to primary disease categories,
and within each category we documented topic-speciﬁc
subsections, including speciﬁc pathogen or disease. We
allocated studies to one of four categories along the
R&D continuum: preclinical; phases I, II or III; product
development; and operational research, and to 1 of the
26 categories for funding organisations.
Where the PI was named, we assigned them to men or
women categories. The studies where only an initial was
available for the forename were assigned as ‘unclear’ if
we were unable to establish the PI’s gender from a
review of the literature, institutional websites or publicly
available publications and documents.
Reference to sexually transmitted infections excludes
HIV. Neglected tropical diseases were categorised accord-
ing to the classiﬁcation used by the WHO (http://www.
who.int/neglected_diseases/diseases/en). Antimicrobial
resistance includes antibacterial, antiviral, antifungal and
antiparasitic studies.
We converted grants awarded in a currency other than
pounds sterling to UK pounds using the mean exchange
rate in the year of the award. We adjusted grant funding
amounts for inﬂation and reported in 2010 UK pounds.
As well as excluding studies not immediately relevant
to infection, we excluded unfunded studies, veterinary
infectious disease research studies (unless there was a
zoonotic component), those exploring the use of viral
vectors to investigate non-communicable diseases, grants
for symposia or meetings or studies with UK contribu-
tions (eg, as a collaborator), but the funding was
awarded to a non-UK institution.
We used Microsoft Excel versions 2000 and 2007 to
categorise studies. Where needed, data were exported
into Microsoft Access (versions 2000 and 2007) and spe-
ciﬁc keyword queries used to select precise sections of
the data for analysis. We used Stata (V.11.0) for statistical
analysis and to generate ﬁgures.
We used fold differences to compare total investment,
number of studies, mean grant and median grant
between men and women according to disease system,
speciﬁc infection and funding organisation.
We used the non-parametric Mann-Whitney rank-sum
test to assess the distribution of funding by gender.
The non-parametric K-sample test on equality of
medians was applied to compare the median funding
by gender, and reported as a χ2 statistic without
Yates’ correction for continuity. The non-parametric
Wilcoxon signed-rank test was applied when comparing
matched data, such as time trends by gender. The sig-
niﬁcance for all tests was deﬁned at the 5% level (two-
sided p=0.05).
We present differences between gender and do
not attempt to investigate or imply bias or inequalities as
we could not access data on unsuccessful grant
applications.
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RESULTS
We identiﬁed 6165 studies from the 325 922 studies
screened that were suitable for inclusion in our analysis.
Of these, we were unable to ascertain the gender of the
PI for 30 studies (0.5%). We excluded 83 studies (1.3%)
that did not specify the PI’s name or gender—these
were funded by the Bill & Melinda Gates Foundation
(Gates Foundation; 38 studies; 0.6%) and the UK
Department for International Development (DFID; 22
studies; 0.4%), accounting for £321.2 million (12.3% of
the total). We included 6052 studies in the ﬁnal analysis,
comprising 4357 grants (72%) awarded to men and
1695 grants (28%) awarded to women, totalling £2.274
billion, of which £1.786 billion (78.5%) were awarded to
men and £488 million (21.5%) to women.
The median value of grant funding was greater for
men (£179 389; IQR £59 146–£371 977) than for women
(£125 556; IQR £30 982–£261 834). Similarly, the mean
Figure 1 Methodology flow chart for filtering studies first by infectious disease and then by gender. BBSRC, Biotechnology and
Biological Sciences Research Council; ESRC, Economic and Social Research Council; PI, principal investigator; R&D, research
and development.
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value of the grant funding was greater for men
(£409 910; SD £840 087) than for women (£288 011; SD
£704 474). Figure 2 shows the distribution of the total
investments and median funding awarded to PIs by
gender over time.
Infectious disease system
Table 1A (see web appendix 1) shows the total invest-
ment, total numbers of studies, mean grant funding,
median grant funding and fold differences in funding
according to nine disease systems and by gender of PI.
We identiﬁed no infectious disease system where women
led the majority of research efforts or were awarded the
majority of funding. Median funding awards were
greater for male PIs across all infectious disease systems,
with the exception of neurological infections and sexu-
ally transmitted infections.
The greatest levels of funding awarded to men and to
women were for research into respiratory infections and
HIV. Men received a total of £312.1 million for research
into respiratory infections compared with £84.4 million
for women—a 3.70-fold difference—and a total of
£290.8 million for HIV research compared with £79.7
million for women—a 3.65-fold difference.
The largest difference between total funding for men
and for women was with gastrointestinal infections
(5.65-fold difference) where women received only 15%
of the total investment (£37 million) and spearheaded
18.9% (149) of the studies and neurological infections
(4.22-fold difference). The smallest difference between
Figure 2 (A) Total investment
over time awarded to male and
female principal investigators. (B)
Median investment over time
awarded to male and female
principal investigators.
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total funding for men and for women was in research
into sexually transmitted infections (1.90-fold differ-
ence), where women received 35% (£45.4 million) of
the total funding and led 49% (182) of the studies.
The mean funding for grants was signiﬁcantly greater
for men (£409 910, SD £840 087) than for women
(£288 011, SD £704 474). The differences in median
funding were statistically signiﬁcant (p>0.01) for gastro-
intestinal infections (men £328 021; SD £458 720)
(women £248 615, SD £433 176), for haematological
infections (men £417 889; SD £914 626) (women
£306 126; SD £819 910) and for HIV (men £649 216; SD
£1 550 920) (women £278 505; SD £545 657).
The median funding for grants showed a similar pattern,
with a signiﬁcantly greater grant funding for men
(£179 389; IQR £59 146–£371 977) than women (£125 556;
IQR £30 983–£261 835). Differences in median funding
were statistically signiﬁcant (p>0.05) for gastrointestinal
infections (men £208 369; IQR £78 852–357 771) (women
£155 066; IQR £43 637–£305 928), for hepatic infections
(men £118 638; IQR £41 342–£269 629) (women £68 620;
IQR £26 720–£221 952) and for HIV (men £163 462; IQR
£39 153–£511 800) (women £114 272; IQR £29 880–
£305 339).
Specific infections
Table 1B (see web appendix 1) shows total investment,
total numbers of studies, mean grant funding, median
grant funding and fold differences in funding according
to speciﬁc infection by gender.
Men received signiﬁcantly higher levels of total
research funding, spearheaded greater numbers of
studies and were awarded greater median and mean
funding for grants for malaria (p=0.01), HIV (p=0.01)
and inﬂuenza (p=0.04).
Major differences between total funding for men and
for women were observed for research into candida
(47.75-fold difference), rotavirus (33.65-fold difference),
Campylobacter (24.33-fold difference) and norovirus
(23.33-fold difference). Smallest differences between
total funding for men and women were observed for
research into dengue (1.07-fold difference) and leish-
maniasis (1.55-fold difference). Women received greater
total funding than men for research into leprosy
(0.09-fold difference), diphtheria (0.18-fold difference),
chlamydia (0.36-fold difference), syphilis (0.37-fold dif-
ference) and varicella zoster (0.54-fold difference).
Differences in mean grant funding were statistically sig-
niﬁcant (p>0.05) for malaria research (men £590 422; SD
£1 324 909) (women £318 054; SD £726 872), for inﬂu-
enza (men £616 643; SD £881 493) (women £387 186; SD
£489 997), for respiratory syncytial virus (men £485 283;
SD £539 396) (women £187 931; SD £268 412) and for
HIV (men £649 216; SD £1 550 920) (women £278 505;
SD £545 657).
Differences in median grant funding were statistically
signiﬁcant (p>0.05) for malaria research (men
£209 646; IQR £63 826–£529 610) (women £143 358;
IQR £42 754–£314 524), for hepatitis C (men £124 797;
IQR £42 475–£289 293) (women £67 265; IQR £29 880–
£233 467), for inﬂuenza (men £348 730; IQR £213 601–
£668 561) (women £200 787; IQR £124 210–£398 191),
for herpes simplex virus (men £119 295; IQR £40 009–
£446 395) (women £309 610; IQR £147 885–£439 305)
and for HIV (men £163 462; IQR £39 153–£511 800)
(women £114 272; IQR £29 880–£305 339).
Figure 3 shows the proportion of total funding awarded
to PIs by gender over time and a breakdown of investment
by research pipeline. The proportion of the total funding
awarded to women ranged from 14.3% (in 1998) to 26.8%
(in 2009), with a mean proportion of 21.4% for the period
studied. The proportion of funding was lowest for preclin-
ical research at 18.2% (£285.5 million of £1.573 billion
total) and highest for operational research at 30.9%
(£151.4 million of £489.7 million). The funding for clin-
ical (phases I–III) research was 29.9% (£25.5 of £85.2)
and for product development it amounted to 20.4%
(£25.8 million of £126.6 million).
Funding organisation
Table 2 (see web appendix 2) shows in detail the total
investment, total numbers of studies, mean grant funding,
median grant funding and fold differences in funding
according to funding organisation and by gender.
Public funding organisations invested a total of £1.025
billion in research led by men (78.6%) and £279.8 in
research led by women (21.4%). The greatest levels of
funding awarded to men and to women were by the
Wellcome Trust and the UK MRC. Major differences
between funding awarded to men and to women PIs were
by the Biotechnology and Biological Sciences Research
Council (BBSRC), with a 6.12-fold difference. Smallest dif-
ferences between funding awarded to men and to women
were by the UK Government funding streams such as the
National Institute for Health Research, with a 1.66-fold dif-
ference. Mean grant funding from public funding organi-
sations was signiﬁcantly greater for men at £595 361 (SD
£1 080 718) than for women at £448 414 (SD £814 979).
Differences were also statistically signiﬁcant (p>0.01) for
UK MRC grants with men at £751 413 (SD £1 020 748)
and women at £544 427 (SD £884 442) and for UK
Government grants with men at £208 828 (SD £492 519)
and women at £182 907 (SD £619 889).
Median grant funding from public funding organisa-
tions had a similar pattern with signiﬁcantly greater grant
funding for men at £272 452 (IQR £138 322–£572 529)
and women at £213 718 (IQR £92 880–£402 917).
Differences were also statistically signiﬁcant (p>0.05) for
UK MRC grants with men at £404 615 (IQR £ 210 068–
£811 860) and women at £286 679 (£178 182 to £468 998),
and for UK Government grants with men at £129 660
(IQR £23 761–£207 320) and women at £59 976 (IQR
£12 564–£157 053).
Philanthropic funding organisations invested a total of
£691.7 million in research led by men (78.8%) and
£185.9 million in research led by women (21.2%).
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Mean grant funding from philanthropic funding organi-
sations was signiﬁcantly greater for men at £338 396 (SD
£695 025) than for women at £242 014 (SD £711 420).
Differences were also statistically signiﬁcant (p>0.01) for
Wellcome Trust grants with men receiving £393 652 (SD
£723 549) and women £230 168 (SD £362 836) and for
other charitable funding organisations with men receiving
£211 190 (SD £454 108) and women £271 842 (SD
£1 208 852).
Median grants from philanthropic funding organisa-
tions showed a similar pattern with signiﬁcantly greater
grant funding for men at £153 653 (IQR £58 589–
£302 774) and women at £114 173 (IQR £42 658–
£222 842). Differences were also statistically signiﬁcant
(p>0.05) for Wellcome Trust grants with men receiving
£191 461 (IQR £74 759–£362 424) and women £137 241
(IQR £54 019–£250 723), and for other charitable funding
organisations with men receiving £91 991 (IQR £36 429–
£172 497) and women £76 058 (IQR £17 279–£150 727).
Figure 4 shows the association between funding organ-
isation and total investment and median funding by
gender. The MRC awarded the highest median amount
in grants to women (£286 679; IQR £178 182–£468 998),
but the median funding amount in grants for men were
1.41-fold higher than that awarded to women (£404 615;
IQR £210 068–£811 860). The European Commission
awarded the highest mean grants to women at £923 364
(SD £1 316 016); however, mean funding amount in
grants for men was 1.44-fold higher at £1 325 149 (SD
£2 409 860) than that for women.
Time trend
Table 3 (see web appendix 3) shows in detail the trends
in funding over time from 1997 to 2010 by gender of
Figure 3 (A) Proportion of
investment over time awarded to
male and female principal
investigators. (B) Total investment
by research pipeline awarded to
male and female principal
investigators.
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PIs, with amounts and relative proportions each year of
funding. Mean annual funding received was greater by
men at £127.6 million (SD £48.7 million) than women
at £34.9 million (SD £13.4 million). Proportions of
annual funding received by men ranged from 73.2% to
85.7%, with a mean of 78.6%.
Proportions of annual funding received by women
ranged from 14.3% to 26.8% with a mean of 21.4%. The
largest annual funding received by men was £245.7
million in 2000, and the smallest at £64.2 million in
1997. The largest annual funding received by women
was £59.6 million in 2002, with the smallest at £13.1
million in 1998.
Over the 14-year study period, the proportion of
investment awarded to women each year remains rela-
tively unchanged with a mean of 21.4% of total (range
14.3–26.8%; £13.1 million to £59.6 million). Figure 5
shows the funding trends over time and fold differences
in total investments by gender. The absolute difference
in the funding amounts in the grants awarded to men
and women ranges between £47.9 million and £190.1
million, with a mean difference of £92.7 million (SD
£38.3 million). The fold difference in grant funding for
men and women ranged from 2.74 to 5.97, with a mean
fold difference of 3.66.
DISCUSSION
We present the ﬁrst detailed and systematic comparison
by sex of investments in infectious disease research in
the UK for the 14-year period 1997–2010. We identiﬁed
6165 studies funded by public and philanthropic
funding organisations, with a total research investment
of £2.6 billion.
Figure 4 (A) Association
between funding organisation and
total investment by gender.
(B) Association between funding
organisation and median award
by gender. BBSRC,
Biotechnology and Biological
Sciences Research Council;
DH, UK department of health;
MRC, Medical Research Council.
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We quantiﬁed the differences in research funding
awarded by gender to show these to be substantial. The
analysis shows clear and consistent differences between
men and women PIs, with lower funding in terms of the
total investment, the number of funded studies, the
median funding awarded and the mean funding
awarded across most of the infectious disease areas
funded. Women received less funding in absolute
amounts and in relative terms, by funder and the type of
science funded along the R&D pipeline. These differ-
ences in funding between men and women persist over
time.
We show large differences in median funding amounts
for men and women researchers in investments by the
European Commission and the MRC. Such differences
were much less apparent when comparing funding from
the Department of Health and BBSRC, although the
BBSRC awarded 86% of funding to men. The BBSRC
almost entirely funds preclinical research,14 and this
matches the increased proportions of preclinical studies
being led by male PIs.
Our ﬁndings in infectious disease research, the most
detailed until now, provide new evidence on differences
between men and women researchers to reinforce the
concerns raised in earlier studies.4 15 16 Differences that
are more marked at senior levels of academia need to
be investigated to explain and account for the observed
differences.
Figure 5 (A) Total investment
and trend over time, by gender.
(B) Fold difference of investment
over time, by gender.
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The reasons why the median awards across most infec-
tious disease conditions should be signiﬁcantly less for
women PIs cannot be deduced from the available data.
Thus, it is not possible to recommend interventions to
address this phenomenon, given that it is unclear if there
is any bias or precisely what mechanisms are at play. The
next step may be to investigate success rates by gender to
assess how many women are applying and what proportion
of the initial request for funding is actually allocated.
There have been suggestions that women are systematic-
ally less ambitious in the amounts of funding requested in
their grant applications when compared with men who are
equivalently ranked academically, and that relatively
simple mentoring programmes could at least partially over-
come this anomaly.3 However, there is no evidence sup-
porting these assertions. Others have suggested that
systems which ensure PI anonymity during review of grant
funding submissions may help reduce the presence of any
subtle gender biases,17 though in practice this approach
would be challenging as the experience of PI is a key
factor when considering the suitability of request for
research support. However, evidence on effective interven-
tions to address barriers for women scientists is lacking.16
Women of childbearing age are being disadvantaged in
some areas of employment, even though in relation to sci-
entiﬁc endeavour, productivity as measured by published
outputs is not signiﬁcantly different between women with
and without children.15
Study limitations
Our analysis has several limitations. We rely on the accur-
acy of the original data from the funding organisations
and, as described elsewhere, we have excluded data
from the private sector as the publicly available data are
incomplete.14
In the period analysed, we were not able to ﬁnd data on
the number of men and women PIs requesting ﬁnancial
support for research agencies from the funding sources
studies. Hence, we were unable to assess the success and
failure rates by gender. We also did not have complete data
on the amount of funding initially requested, the gender
of coapplicants for each study, the total pool of researchers
in each disease area and within each type of science, or
the proportion of awards made to clinical and non-clinical
researchers, all of which would be useful pieces of infor-
mation in developing a clearer picture of the reasons for
the presented differences. The proportion of doctors
registered in the UK favours men (56.8% as of January
2013) over women,18 but the proportion of those carrying
out research appears to be unknown. Understanding the
distribution of researchers is critical to an understanding
of the research landscape.
We lacked data on the academic ranking of PIs and
were hence unable to adjust for levels of seniority across
both genders. We were unable to get data on gender
from the Gates Foundation and DFID and hence were
unable to clarify the gender of a small proportion of
investigators, though we believe this limitation is not
likely to change the conclusions of the study. Our ana-
lysis focuses on infectious disease research, and analysis
of other areas of scientiﬁc research would be needed if
these differences persisted for all research areas.
CONCLUSIONS
Notwithstanding the limitations, our systematic analysis
shows an unequal distribution of investments in infec-
tious disease research for men and women. There are
fewer women receiving funding as PIs in infectious
disease research, with fewer studies funded with lower
funding amounts when successful.
Although earlier studies have discussed possible solu-
tions, including mentoring programmes and advertising
campaigns, none have systematically explored the
reasons why such differences persist. Hence, without an
understanding of the reasons for the observed differ-
ences, the proposed solutions are not very meaningful.
There is no evidence that women and men researchers
are not equally capable; hence, other factors are likely
to be at play to explain the observed differences which
have persisted over the 14-year study period. From our
data, the limitations mean that we cannot explain what
these mechanisms might be. Research is needed to elu-
cidate an understanding of the factors that can explain
the observed differences. A subanalysis of our dataset
where information on academic rank at the time of
award is obtained would allow for more meaningful con-
clusions. We strongly urge policy-makers, funders and
scientists to urgently investigate the factors leading to
the observed differences and develop policies developed
to address them, in order to ensure that women are
appropriately supported in scientiﬁc endeavour.
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